PD-1/PD-L1抑制剂的临床研究进展

Clinical research progress of PD-1/PD-L1 antibodies

继手术、化疗、放疗和靶向治疗之后,肿瘤免疫疗法现已广泛应用于临床。针对免疫检查点的单抗在抗癌治疗中取得了非常好的成绩,其中靶向PD-1/PD-L1的单抗显示出高效、低毒的优势。本文概述PD-1及其配体、PD-1/PD-L1信号通路及其靶向药物的临床研究进展。

Cancer immunotherapy has been widely used in the patients who complete surgical excision, chemotherapy, radio-therapy, and targeted therapy. In recent years, monoclonoantibodies against immune checkpoints have achieved very good results in clinical oncology. The antibodies targeting either PD-1 or PD-L1 show signifi cant anti-tumor activity with lower toxicity. This review summarizes PD-1 and its ligands, PD-1/PD-L1 signaling pathway as well as the application of PD-1 antibody in tumor therapy.